Abstract |
Common variable immunodeficiency is the most common symptomatic primary immunodeficiency in adulthood. Pregnant women with common variable immunodeficiency have different needs from other patients with the same disease. Because of immature state of the fetal and neonatal immune system, transplacental transfer of immunoglobulin G ( IgG) has a relevant role in protecting the infant. We here report on a high-risk pregnant woman with common variable immunodeficiency with adverse reactions to intravenous immunoglobulin that was successfully rescued with a new Ig human intravenous, 10% liquid preparation. The treatment was tailored to the health status and characteristics of the patient. The new product was safe and well tolerated. The mother did not report any infections during pregnancy and the baby had a healthy course with 'protective' serum IgG levels. Our case is a further demonstration that intravenous immunoglobulin tolerability in patients with immunodeficiency could be linked to a product's characteristics.
|
Authors | Maria Giovanna Danieli, Romina Moretti, Lucia Pettinari, Simona Gambini |
Journal | BMJ case reports
(BMJ Case Rep)
Vol. 2012
(Dec 17 2012)
ISSN: 1757-790X [Electronic] England |
PMID | 23257273
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- Immunoglobulins, Intravenous
- Immunologic Factors
|
Topics |
- Adult
- Common Variable Immunodeficiency
(drug therapy)
- Female
- Humans
- Immunoglobulins, Intravenous
(adverse effects, therapeutic use)
- Immunologic Factors
(therapeutic use)
- Pregnancy
- Pregnancy Complications
(drug therapy, immunology)
|